Lebanon has recorded its first case of the often-fatal Middle East respiratory virus, the Health Ministry said Friday.
The virus was detected Thursday in a man who had checked into a local hospital after feeling ill, the ministry said. It said the case was not severe, and the man has since been discharged.
A ministry official said the patient had recently returned from a visit to several Gulf countries, including Saudi Arabia.
The kingdom has been the focal point of the outbreak of the virus, known as the Middle East Respiratory Syndrome.
MERS belongs to a family of viruses that include both the common cold and SARS, which killed some 800 people in a global outbreak in 2003. It can cause symptoms that include fever, breathing problems, pneumonia and kidney failure.
Not everyone who contracts the virus that causes MERS gets sick, while others show only mild symptoms. There is no cure or vaccine.
Still, the threat from the virus has prompted health officials around the region to adopt protective measures to try to prevent the spread of the disease.
In Lebanon, the health minister on Thursday ordered that thermal cameras be set up at Beirut's international airport to check arriving passengers for possible signs of fever, indicating a possible MERS infection.
Five more people have died in Saudi Arabia after contracting an often fatal Middle East respiratory virus as the number of new infections in the kingdom climbs higher, health officials confirmed Thursday.
Reported cases of gonorrhea continue to increase in Norway, both among men who have sex with men (MSM) and among heterosexuals. The increase of gonorrhea among heterosexual women was particularly significant. ...
Vets across the UK are set to take part in the Big Tick Project, the largest nationwide collection of ticks from dogs in a bid to help scientists, led by Professor Richard Wall at the University of Bristol, ...
Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These ...
Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with ...
New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation ...
Please sign in to add a comment.
Registration is free, and takes less than a minute.
Click here to reset your password.
Sign in to get notified via email when new comments are made.